Literature DB >> 8413836

BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors.

N R Newberry1, C J Watkins, T S Sprosen, T P Blackburn, D G Grahame-Smith, R A Leslie.   

Abstract

The effect of a novel 5-HT3 receptor antagonist, BRL 46470, has been studied on two electrophysiological models for 5-HT3 receptors: grease-gap recordings from rat isolated vagus nerve and whole-cell patch-clamp recordings from mouse neuroblastoma-rat glioma NG108-15 cells. Its action on the rat vagus nerve was compared to that of four other 5-HT3 receptor antagonists. On the rat vagus, BRL 46470 reduced the maximum depolarizing response to 5-HT in a concentration-dependent manner with an IC50 of 0.3-1.0 nM, but the EC50 for 5-HT was not appreciably affected. This action was similar to that of granisetron and ICS 205-930, but differed from that of GR38032F and (+)-tubocurarine which produced clear rightward shifts of the concentration-response curve to 5-HT. The 5-HT-induced fast inward current of voltage-clamped NG108-15 cells was also antagonized by 1 nM BRL 46470 in an insurmountable manner. In contrast to (+)-tubocurarine, the action of BRL 46470 on the rat vagus nerve and NG108-15 cells did not readily reverse on washing with antagonist-free medium. It is concluded that BRL 46470 is a potent, insurmountable 5-HT3 receptor antagonist on the rat vagus and NG108-15 cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8413836     DOI: 10.1016/0028-3908(93)90180-b

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  13 in total

1.  Multiple 5-HT receptors in the guinea-pig superior cervical ganglion.

Authors:  C J Watkins; N R Newberry
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

Review 2.  A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis.

Authors:  E A Perez
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 3.  Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics.

Authors:  Cesare Gridelli
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 4.  Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?

Authors:  Tong J Gan
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Evidence that the atypical 5-HT3 receptor ligand, [3H]-BRL46470, labels additional 5-HT3 binding sites compared to [3H]-granisetron.

Authors:  L J Steward; J Ge; K R Bentley; P C Barber; A G Hope; J J Lambert; J A Peters; T P Blackburn; N M Barnes
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

Review 6.  Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients.

Authors:  Cesare Gridelli; Matti Aapro
Journal:  Support Care Cancer       Date:  2004-03-04       Impact factor: 3.603

7.  Electrophysiological consequences of ligand binding to the desensitized 5-HT3 receptor in mammalian NG108-15 cells.

Authors:  J T Bartrup; N R Newberry
Journal:  J Physiol       Date:  1996-02-01       Impact factor: 5.182

Review 8.  Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.

Authors:  Y E Yarker; D McTavish
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

9.  Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?

Authors:  P Blower; M Aapro
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

10.  Management of postoperative nausea and vomiting: focus on palonosetron.

Authors:  Neil A Muchatuta; Michael J Paech
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.